A for augmented: Cambridge AI company out to capture biomedical knowledge gets $60M from Mayo, Silicon Valley VC

Amber Tong

Senior Editor

The Mayo Clinic is joining hands with a Silicon Valley VC firm to inject $60 million into nference, a Cambridge, MA-based player in the gold rush to capitalize on biopharma’s growing interest — and urge — to accelerate drug discovery and development using the latest machine learning tools.

While nference ostensibly belongs to a generation of software startups that cropped up around 2013, it doesn’t see itself as part of the AI mainstream, founder and CSO Venky Soundararajan tells Endpoints News. That’s why the A in their AI stands for augmented, not artificial.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

A for augmented: Cambridge AI company out to capture biomedical knowledge gets $60M from Mayo, Silicon Valley VC

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

Madrigal raises $500M for NASH drug launch, discloses cyberattack

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

Data Quality 2.0: The Future of Real-World Evidence

A for aug­ment­ed: Cam­bridge AI com­pa­ny out to cap­ture bio­med­ical knowl­edge gets $60M from Mayo, Sil­i­con Val­ley VC

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

Madri­gal rais­es $500M for NASH drug launch, dis­clos­es cy­ber­at­tack

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

A for augmented: Cambridge AI company out to capture biomedical knowledge gets $60M from Mayo, Silicon Valley VC

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

Madrigal raises $500M for NASH drug launch, discloses cyberattack

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

Data Quality 2.0: The Future of Real-World Evidence